Vanberra Signal
Free trial

Iktos

Curated by Signal

Artificial Intelligence for new drug design

Health Technologyiktos.ai

Overview

Iktos offers artificial intelligence for new drug design. The company is using artificial intelligence technology for ligand-based de novo drug design and focusing on multiparametric optimization (MPO). Their platform can design new, druggable and synthesizable molecules according to particular criteria. Their technology is based on deep learning algorithms.

Key facts

Founded
2016
Headquarters
Paris, France
Stage
Sign up to view
Industry
Health Technology

Business model

3 products and services
Sign up to view

Contact

Email
Sign up to view

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

  • Umanlife

    Online personal health data aggregation and recommendations platform

    Health TechnologyParis, France

  • PMSIpilot

    Software solutions for healthcare industry

    Health TechnologyLyon, France

  • L'Orange Bleue

    Provider of personalized expert-led fitness coaching programs

    Health TechnologyRennes, France

About Iktos

What does Iktos do?

Iktos offers artificial intelligence for new drug design.

Where is Iktos headquartered?

Iktos is headquartered in Paris, France.

When was Iktos founded?

Iktos was founded in 2016.

Which sector is Iktos in?

Iktos operates in Health Technology.

Who are Iktos's competitors?

Companies similar to Iktos include Umanlife, PMSIpilot, and L'Orange Bleue.